Related Experiment Videos
Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and
J Tedroff1, S M Aquilonius, P G Hartvig
1Department of Neurology, University Hospital, Uppsala, Sweden.
Advances in Neurology
|January 1, 1996
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent.
The Journal of pharmacology and experimental therapeutics·2020
News ways of understanding the complex biology of diabetes using PET.
Nuclear medicine and biology·2020
Endogenous compounds labeled with radionuclides of short half-life-some perspectives.
Journal of labelled compounds & radiopharmaceuticals·2013
Brain activation in young and older adults during implicit and explicit retrieval.
Journal of cognitive neuroscience·2013
The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans.
European journal of clinical pharmacology·2012
Behavior therapy: other interventions for tic disorders.
Advances in neurology·2006
Treatment of aggression in Tourette syndrome.
Advances in neurology·2006
Treatment of co-morbid obsessive compulsive disorder, mood, and anxiety disorders.
Advances in neurology·2006
Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs.
Advances in neurology·2006
Preclinical models relevant to Tourette syndrome.
Advances in neurology·2006
Comparative drug survival of biologic classes in psoriasis: a Japanese single-centre cohort study.
European journal of dermatology : EJD·2026
Biologic treatments for palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis.
European journal of dermatology : EJD·2026
Safety and Efficacy of Doravirine/Islatravir (100 mg/0.25 mg) Once Daily after Islatravir Dose Reduction from 0.75 mg: Week 96 Results from an Open-Label Phase 3 Study in Adults with HIV-1.
Journal of acquired immune deficiency syndromes (1999)·2026
Target engagement and efficacy in disease-modifying trials of synuclein-related disorders.
Brain : a journal of neurology·2026